GLP-1 coverage in California (2026)

Medicaid rules, licensing, compounding, and cash prices, each with its source

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.

Content current as of September 2026; updated when guidance or availability changes.

Last verified September 15, 2026by WeighedHealth Editorial Team against primary sources

California Medicaid

Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

Source: Medi-Cal Rx: GLP-1s for weight loss not a covered benefit (October 2025)

Commercial plans set their own rules. See the criteria each carrier publishes on our insurance coverage pages.

Compounded GLP-1s

On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Source: FDA press announcement (April 30, 2026)
Source: Federal Register 91 FR 23431 (May 1, 2026)
Source: Federal Register: comment period extended (June 26, 2026)

Background: our guide to compounding rules.

Cash prices without insurance

NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.

Source: NovoCare Pharmacy: Wegovy offer
Source: LillyDirect: Zepbound

Adult obesity rate: CDC Adult Obesity Prevalence Maps (BRFSS 2024).

GLP-1 in California: common questions

Does California Medicaid cover Wegovy or Zepbound for weight loss?+

Not covered. Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

Is compounded semaglutide still legal in California?+

Compounding rules for semaglutide and tirzepatide are set federally, not by California. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

What does Wegovy or Zepbound cost without insurance in California?+

Manufacturer cash prices are the same in every state. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.